Tralokinumab
Pronunciation: (tra-LOE-ki-nu-mab).
- Generic name
- Tralokinumab
- Brand names
- Adbry, Tralokizumab, Tralozumab, Adtralza
- Drug class
- Monoclonal Antibody; Interleukin-13 (IL-13) Antagonist
Availability and supply rules vary by country
Trade names by country: United States
Australia: · Full directory
What Tralokinumab is and how it works
Uses, formulations, monitoring, and supply rules can differ by patient, product, and country. Follow the exact local product information and professional advice.
Mechanism of action: how Tralokinumab works
Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to interleukin-13 (IL-13), a cytokine involved in the pathogenesis of atopic dermatitis. By inhibiting IL-13 signaling, tralokinumab reduces inflammation, pruritus, and skin barrier dysfunction associated with eczema. (2)
What Tralokinumab is used for
Moderate-to-severe atopic dermatitis (eczema) in adults and adolescents (12 years and older) who are candidates for systemic therapy
Moderate-to-severe atopic dermatitis (eczema) in adults and adolescents (12 years and older) who are candidates for systemic therapy (2)
Before taking Tralokinumab
Do not take / not appropriate for
- Contraindicated in patients with known hypersensitivity to tralokinumab or its excipients. (Contraindication) (2)
- Live vaccines should be avoided during therapy. (Contraindication) (2)
Tell your clinician about
(2)How to take Tralokinumab
- General Instructions: Use tralokinumab exactly as prescribed. It is given as a subcutaneous injection, typically every two weeks after an initial loading dose.. Adult Dosing: Initial dose: 600 mg (four 150 mg injections) subcutaneously, then 300 mg (two 150 mg injections) every two weeks.. Pediatric Dosing: Not approved for children under 12 years. For adolescents (12-17 years), dosing may be weight-based and should follow specialist guidance.. Administration: Inject under the skin of the thigh, abdomen, or upper arm. Rotate injection sites and do not inject into irritated or damaged skin.. When To Stop: Seek medical attention promptly if you develop a severe allergic reaction or a serious infection, and let the clinician you see advise on whether to continue or stop treatment.. Storage: Store in the refrigerator (36°F to 46°F/2°C to 8°C). Protect from light. Do not freeze. Allow to reach room temperature before injection.
- This page does not provide a dose calculator. Dosing must follow the prescriber, pharmacist, or product label.
Procedures and treatment changes
Tell the treating team before surgery, procedures, or any medicine change. Do not alter treatment without the responsible clinician. (2)
Missed dose
If you miss a dose, inject it as soon as you remember. Then resume your regular schedule. Do not double up doses.
Overdose
There is limited information on overdose. If an overdose is suspected, seek immediate medical attention. Supportive care and monitoring are recommended. (2)
Side effects
Side effects and their urgency vary; report severe, persistent, or concerning symptoms to a healthcare professional.
Upper respiratory tract infections
Incidence: FDA label: approximately 23.8% in the monotherapy trial group at Week 16
Conjunctivitis
Incidence: FDA label: approximately 7.5% in the monotherapy trial group at Week 16
Injection site reactions
Incidence: FDA label: approximately 7.4% in the monotherapy trial group at Week 16
Eosinophilia (elevated eosinophil count on blood tests)
Incidence: FDA label: approximately 1.4% in the monotherapy trial group at Week 16
Signs of a hypersensitivity reaction, including anaphylaxis or angioedema — breathing problems, facial or throat swelling, hives, or fainting
(2)New onset or worsening eye symptoms (conjunctivitis or keratitis)
(2)Serious warnings
May increase risk of eye disorders such as conjunctivitis — serious
Symptoms: May increase risk of eye disorders such as conjunctivitis. May increase risk of certain infections. Not recommended for use with live vaccines. Use caution in patients with pre-existing eye disease. Safety in pregnancy and breastfeeding is not established.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Contraindications recorded in the clinician database — serious
Symptoms: Contraindications recorded in the clinician database: Contraindicated in patients with known hypersensitivity to tralokinumab or its excipients. Use with caution in patients with a history of chronic or recurrent infections, active eye disease, or immunosuppression. Live vaccines should be avoided during therapy.
Action: Follow the urgency stated and seek prompt or emergency care when indicated. (2)
Interactions
| Medicine or test | Effect | Action |
|---|---|---|
| Recorded interactions | Tralokinumab has a low potential for drug-drug interactions as it is a monoclonal antibody. However, avoid live vaccines during treatment. Inform your healthcare provider about all medicines and supplements you are taking. | (2) |
Pregnancy, breastfeeding, kidney/liver function, age
Pregnancy
Requires a primary-source research pass before this section can be completed. (2)
Breastfeeding
Requires a primary-source research pass before this section can be completed. (2)
Children
Frequency: Not applicable.. Weight Based: Not recommended for pediatric use.. Max Daily Dose: Not applicable.. Max Single Dose: Not applicable.. Age Restrictions: Safety not established in children. (2)
Renal_impairment
Requires a primary-source research pass before this section can be completed. (2)
Hepatic_impairment
Requires a primary-source research pass before this section can be completed. (2)
Monitoring
(2)Storage
Requires a primary-source research pass before this section can be completed.
Professional information
Clinician-facing context only. This section does not replace current product labeling.
General
Indication: Moderate-to-severe atopic dermatitis (eczema)
Dose summary: Initial dose of 600 mg administered subcutaneously, followed by 300 mg every 2 weeks.
Renal context: FDA label (Adbry): no clinically significant differences in tralokinumab pharmacokinetics were observed for patients with mild to moderate renal impairment, so no dose adjustment is specified for that group. The effect of severe renal impairment on tralokinumab pharmacokinetics is unknown, so dosing in that group should be individualized with clinician oversight. (2)
Hepatic guidance
FDA label (Adbry): no clinically significant differences in tralokinumab pharmacokinetics were observed for patients with mild hepatic impairment, so no dose adjustment is specified for that group. The effect of moderate-to-severe hepatic impairment on tralokinumab pharmacokinetics is unknown, so dosing in that group should be individualized with clinician oversight.
Frequently asked questions
What is tralokinumab used for?
Tralokinumab is used to treat moderate to severe atopic dermatitis (eczema) in adults and adolescents who are candidates for systemic therapy.
How does tralokinumab work?
It works by blocking interleukin-13 (IL-13), a protein that causes inflammation and itching in eczema.
How is tralokinumab administered?
It is given as a subcutaneous injection, usually every two weeks after an initial loading dose.
What are the most common side effects?
Common side effects include upper respiratory infections, injection site reactions, and conjunctivitis.
Can I receive vaccines while on tralokinumab?
You should avoid live vaccines during treatment. Inactivated vaccines are generally considered safe, but discuss with your healthcare provider.
Is tralokinumab safe during pregnancy or breastfeeding?
Safety in pregnancy and breastfeeding is not established. Use only if the potential benefit justifies the potential risk.
What should I do if I miss a dose?
Inject the missed dose as soon as you remember, then continue your regular schedule. Do not take two doses at once.
What happens if I take too much Tralokinumab?
If you suspect an overdose of Tralokinumab, it is crucial to seek immediate medical attention. While specific overdose symptoms for Tralokinumab are not extensively documented, general adverse effects may be exacerbated. Contact your healthcare provider or emergency services without delay for guidance and appropriate management to ensure your safety and well-being.
Can I drink alcohol while taking Tralokinumab?
There are no specific known interactions between Tralokinumab and alcohol. However, alcohol consumption can sometimes exacerbate inflammatory conditions or cause liver stress, which might be a concern for individuals with underlying health issues. It is always best to discuss alcohol intake with your healthcare provider to ensure it does not interfere with your treatment or overall health.
Is Tralokinumab safe during pregnancy?
Tralokinumab's pregnancy category requires consultation with a doctor. Animal studies have shown potential risks, and there is limited data on human pregnancy. Therefore, it is essential to discuss the potential benefits and risks with your healthcare provider if you are pregnant, planning to become pregnant, or breastfeeding. They can provide personalized advice based on your individual circumstances.
What is the mechanism of action of Tralokinumab?
Tralokinumab is a fully human IgG4 monoclonal antibody that specifically binds to interleukin-13 (IL-13), a cytokine involved in the pathogenesis of atopic dermatitis. By inhibiting IL-13 signaling, tralokinumab reduces inflammation, pruritus, and skin barrier dysfunction associated with eczema. (2)
What is the generic name of Tralokinumab?
The generic name is Tralokinumab. It is sold under brand names including Adbry, Tralokizumab, Tralozumab, Adtralza.
What class of drug is Tralokinumab?
Tralokinumab is classed as: Monoclonal Antibody; Interleukin-13 (IL-13) Antagonist.
References
- Clinician-authored medicine record for Tralokinumab (MedGuideGlobal medicines database) · · accessed 2026-08-07 · source 1
- ADBRY (tralokinumab-ldrm) injection — FDA prescribing information, DailyMed · · accessed 2026-08-07 · source 2
- Tralokinumab-ldrm injection — patient drug information (MedlinePlus)U.S. National Library of Medicine (MedlinePlus) · US · accessed 2026-08-14 · source 3
- Adbry — FDA approval record (Drugs@FDA BLA761180)U.S. Food and Drug Administration · US · accessed 2026-08-14 · source 4
- Tralokinumab — RxNorm normalized drug concept (RXCUI 2589225)U.S. National Library of Medicine (RxNorm) · US · accessed 2026-08-14 · source 5
Brand names by country
Single-ingredient Tralokinumab names are shown separately by country. Product availability, strengths, and supply rules can change; combination products are not included here.
Priority countries
United States
- Adbry300 mg/2mL, 150 mg/mL · leo pharma inc.